瑞士诺华的地拉罗司哪里能买到

It was developed by Novartis and was the first oral iron chelator approved by the FDA for routine use in 2005. The FDA also granted deferasirox orphan drug status for the treatment of iron overload in non-transfusion-dependent thalassemia. It is currently on the market in more than 80 countries. Novartis is a leading multinational company in the global pharmaceutical and consumer health care industries. Its English name is Novartis.

Deferasirox can remove free iron and intracellular iron, prevent myocardial cells from taking up iron, and directly remove excess iron from myocardial cells, resulting in a continuous reduction of non-transferrin in plasma. It is the first-line drug for patients with chronic iron overload caused by blood transfusion. The use of deferasirox effectively reduced patients' mortality and improved their quality of life.

Where can I buy deferasirox from Novartis Switzerland?

In 2010, the Swiss Novartis deferasirox was approved for marketing in my country, so patients can buy it in some domestic hospitals. It is understood that the domestic price of the original drug deferasirox is around 2,300$, and the price may vary in different regions. Overall, the price is relatively high, which is a relatively large financial burden for many patients.

In addition to my country, Novartis has also launched it in other countries. We learned that the current lower-priced version is 400mg*30 tablets and the price is around 420$, which is much lower than the domestic price. If you need Swiss Novartis deferasirox at a relatively low price, you can consult the Medical Partner Travel Overseas Medical Consulting Service Company for formal purchase methods.

Recommended related hot articles: /newsDetail/93998.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.